Quick Takeaways
- ADXN - Addex Therapeutics Ltd. has 8 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 8 Insiders of Addex Therapeutics Ltd.
- Symbol
- ADXN on Nasdaq
- Location
- Geneva, Switzerland
What Changed
- No meaningful buy/sell imbalance is currently visible in the one-year window.
- Activity will update as new Forms 3/4/5 are filed.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsInsider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 17 May 2025.
Buys
$0
Shares: 0
Insiders: 0
Sells
$0
Shares: 0
Insiders: 0
Net
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Addex Therapeutics Ltd. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Isaac Manke | Director | Mixed | 18 Mar 2026 | |||
| Jason Raleigh Nunn | Director | Mixed | 18 Mar 2026 | |||
| Timothy Mark Dyer | Chief Executive Officer, Director, 10%+ Owner | Mixed | 18 Mar 2026 | |||
| Raymond George Hill | Director | Mixed | 18 Mar 2026 | |||
| Mikhail Kalinichev | Head Of Translational Science | Mixed | 18 Mar 2026 | |||
| Lenaic Nathanael Teyssedou | Principal Accounting Officer | Mixed | 18 Mar 2026 | |||
| Vincent Michael Lawton | Director | Mixed | 18 Mar 2026 | |||
| Roger Mills | CHIEF MEDICAL OFFICER, Director | Mixed | 18 Mar 2026 |
Top shareholders of Addex Therapeutics Ltd. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Timothy Mark Dyer |
13D/G
3/4/5
|
Chief Executive Officer, Director, 10%+ Owner |
13%
|
18,208,437
|
$153,679,208 | $0 | 20 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
301
|
$1,893 | — | 31 Mar 2026 | |
| GAMMA Investing LLC |
13F
|
Company |
0%
|
81
|
$509 | — | 31 Mar 2026 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0%
|
72
|
$450 | — | 31 Mar 2026 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
1
|
$6 | — | 31 Mar 2026 | |
| Vincent Michael Lawton |
3/4/5
|
Director |
—
class O/S missing
|
2,507,987
|
— | — | 18 Mar 2026 | |
| Raymond George Hill |
3/4/5
|
Director |
—
class O/S missing
|
1,365,532
|
— | — | 18 Mar 2026 | |
| Roger Mills |
3/4/5
|
CHIEF MEDICAL OFFICER, Director |
—
class O/S missing
|
785,976
|
— | — | 18 Mar 2026 | |
| Mikhail Kalinichev |
3/4/5
|
HEAD OF TRANSLATIONAL SCIENCE |
—
class O/S missing
|
306,765
|
— | — | 18 Mar 2026 | |
| Isaac Manke |
3/4/5
|
Director |
—
class O/S missing
|
219,561
|
— | — | 18 Mar 2026 | |
| Jason Raleigh Nunn |
3/4/5
|
Director |
—
class O/S missing
|
219,561
|
— | — | 18 Mar 2026 |
Recent Insider Transactions by Companies or Individuals for Addex Therapeutics Ltd.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Roger Mills | ADXN | Common Stock | 0 | 785,976 | 18 Mar 2026 | Direct | ||||
| Vincent Michael Lawton | ADXN | Common Stock | 0 | 2,507,987 | 18 Mar 2026 | Direct | ||||
| Mikhail Kalinichev | ADXN | Common Stock | 0 | 306,765 | 18 Mar 2026 | Direct | ||||
| Raymond George Hill | ADXN | Common stock | 0 | 1,365,532 | 18 Mar 2026 | Direct | ||||
| Timothy Mark Dyer | ADXN | Common stock | 0 | 16,848,979 | 18 Mar 2026 | Direct | ||||
| Jason Raleigh Nunn | ADXN | Common Stock | 0 | 219,561 | 18 Mar 2026 | Direct | ||||
| Isaac Manke | ADXN | Common Stock | 0 | 219,561 | 18 Mar 2026 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.